Myricetin is categorized under the secondary metabolite flavonoid which includes a diverse range of consumable plant parts, and it has a potential against several classes of cancer including cancers and tumors. In the present study, the anticancer potential of the unique flavonoid-myricetin in A549 lung cancer cells was evaluated. Among different doses of myricetin, 73 μg/ml was more effective to prevent the cancer cell growth. It also promoted sub-G1 phase aggregation of cells and a equivalent decrease in the fraction of cells entering the S and subsequent phase which indicates apoptotic cell death. Myricetin generated enormous free radicals and, altered the potential of mitochondrial membrane in A549 cells as paralleled to untreated cells. In addition, myricetin treatment intensified the expression of P53 and relegated the expression of EGFR in A549 cells. These results suggested that myricetin exhibits cytotoxic potential by arresting the progression of cell cycle and ROS-dependent mitochondria-mediated mortality in cancer A549 lung cancer cells and it would be useful to develop as a drug candidate for lung cancer therapeutics. In silico experiments were carried out against human EGFR and P53 tumor suppressor protein to gain more insights into the binding mode of the myricetin may act as significant potential for anticancer therapy.

中文翻译：

---

杨梅素：通过诱导细胞周期停滞和 ROS 依赖的线粒体促进 A549 肺癌细胞凋亡和计算机预测，用于癌症治疗的多功能植物类黄酮。

杨梅素属于次生代谢产物类黄酮，其中包括多种可食用的植物部分，它具有对抗多种癌症（包括癌症和肿瘤）的潜力。在本研究中，评估了独特的黄酮类 - 杨梅素在 A549 肺癌细胞中的抗癌潜力。在不同剂量的杨梅素中，73 μg/ml 更有效地阻止癌细胞生长。它还促进了亚 G1 期细胞的聚集和进入 S 期和随后表明细胞凋亡的细胞比例的等效减少。杨梅素产生大量自由基，并改变 A549 细胞线粒体膜的电位，与未处理的细胞平行。此外，杨梅素处理增强了 P53 的表达并降低了 A549 细胞中 EGFR 的表达。这些结果表明，杨梅素通过阻止癌症 A549 肺癌细胞中细胞周期的进展和 ROS 依赖性线粒体介导的死亡率而表现出细胞毒性潜力，并且将有助于开发为肺癌治疗的候选药物。对人 EGFR 和 P53 肿瘤抑制蛋白进行了计算机模拟实验，以更深入地了解杨梅素的结合模式可能作为抗癌治疗的重要潜力。这些结果表明，杨梅素通过阻止癌症 A549 肺癌细胞中细胞周期的进展和 ROS 依赖性线粒体介导的死亡率而表现出细胞毒性潜力，并且将有助于开发为肺癌治疗的候选药物。对人 EGFR 和 P53 肿瘤抑制蛋白进行了计算机模拟实验，以更深入地了解杨梅素的结合模式可能作为抗癌治疗的重要潜力。这些结果表明，杨梅素通过阻止癌症 A549 肺癌细胞中细胞周期的进展和 ROS 依赖性线粒体介导的死亡率而表现出细胞毒性潜力，并且将有助于开发为肺癌治疗的候选药物。对人 EGFR 和 P53 肿瘤抑制蛋白进行了计算机模拟实验，以更深入地了解杨梅素的结合模式可能作为抗癌治疗的重要潜力。